Thymosin Alpha-1 Treats CMV Infection With ARDS: Clinical Immune Restoration

Thymosin alpha-1 treatment of cytomegalovirus infection with acute respiratory distress syndrome improved immune function and clinical outcomes, demonstrating its value for severe viral infections in immunocompromised patients.

Ji, S-M et al.·Transplantation proceedings·2007·Moderate Evidenceclinical-trial
RPEP-01246Clinical TrialModerate Evidence2007RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-trial
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Thymosin alpha-1 enhanced immune function (CD4+/CD8+ T-cells, NK cells) and improved clinical outcomes in patients with CMV infection complicated by ARDS, demonstrating clinical efficacy for severe opportunistic viral infections.

Key Numbers

How They Did This

clinical-trial study on thymosin-alpha-1, infection.

Why This Research Matters

Relevant for thymosin-alpha-1, infection, immune-function.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Thymosin alpha-1 enhanced immune function (CD4+/CD8+ T-cells, NK cells) and improved clinical outcomes in patients with CMV infection complicated by A
Evidence Grade:
moderate evidence.
Study Age:
Published in 2007.
Original Title:
Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation.
Published In:
Transplantation proceedings, 39(1), 115-9 (2007)
Database ID:
RPEP-01246

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What was studied?

Thymosin Alpha-1 Treats CMV Infection With ARDS: Clinical Immune Restoration

What was found?

Thymosin alpha-1 treatment of cytomegalovirus infection with acute respiratory distress syndrome improved immune function and clinical outcomes, demonstrating its value for severe viral infections in immunocompromised patients.

Read More on RethinkPeptides

Cite This Study

RPEP-01246·https://rethinkpeptides.com/research/RPEP-01246

APA

Ji, S-M; Li, L-S; Sun, Q-Q; Chen, J-S; Sha, G-Z; Liu, Z-H. (2007). Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation.. Transplantation proceedings, 39(1), 115-9.

MLA

Ji, S-M, et al. "Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation.." Transplantation proceedings, 2007.

RethinkPeptides

RethinkPeptides Research Database. "Immunoregulation of thymosin alpha 1 treatment of cytomegalo..." RPEP-01246. Retrieved from https://rethinkpeptides.com/research/ji-2007-immunoregulation-of-thymosin-alpha

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.